Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1243

Shown on this page

Current sort

Live official records

Conditions: Bipolar Disorder Type I With Mania
Interventions: KarXT, Lithium, Valproate, Lamotrigine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 61
States / cities: Glendale, Arizona • Scottsdale, Arizona • Tucson, Arizona + 49 more

Conditions: End Stage Renal Disease on Dialysis
Interventions: Empagliflozin 25 mg vs Placebo, Empagliflozin 10 MG; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Immune Thrombocytopenia
Interventions: INCA000585; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Glendale, Arizona • Los Angeles, California • Lone Tree, Colorado + 6 more

Conditions: Ovarian Cancer, Non-small Cell Lung Cancer
Interventions: TUB-040; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • New Haven, Connecticut • Atlanta, Georgia + 15 more

Conditions: Multiple Sclerosis
Interventions: RO7121932 IV, RO7121932 SC; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Stanford, California • New Haven, Connecticut

Conditions: Myelofibrosis (MF)
Interventions: Not applicable- observational study; Other
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: New Haven, Connecticut • Columbus, Ohio • Charleston, South Carolina

Conditions: Advanced Solid Tumors
Interventions: BG-C477, Tislelizumab, Chemotherapy; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 10
States / cities: Goodyear, Arizona • Duarte, California • Aurora, Colorado + 7 more

Conditions: Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma, Hepatoblastoma, Hepatocellular Malignant Neoplasm, Not Otherwise Specified
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Patient Observation, Resection, Sorafenib, Vincristine Sulfate; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 180
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 134 more

Conditions: Prostate Cancer
Interventions: Relugolix 120 MG [Orgovyx], SBRT standard of care radiotherapy treatment; Drug · Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: New Haven, Connecticut • Lebanon, New Hampshire • New York, New York + 1 more

Conditions: Cirrhosis, Liver Failure
Interventions: Empagliflozin 10 MG, Matching Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Mantle Cell Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human; Procedure · Biological
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years to 70 Years
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 374
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 236 more

Conditions: Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Magnetic Resonance Imaging, Memantine Hydrochloride, Neurocognitive Assessment, Stereotactic Radiosurgery, Survey Administration, Whole-Brain Radiotherapy; Procedure · Drug · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 227
States / cities: Phoenix, Arizona • Anaheim, California • Bellflower, California + 172 more

About this Yale institution page

What this page lists: ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Yale

Filter and sort this campus

Live official records

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

Pacritinib Effectiveness in Real-world Settings

A Study of BG-C477 in Participants With Advanced Solid Tumors

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

Empagliflozin in Patients With Cirrhosis and Ascites

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

About this Yale institution page